4-[4-(2-oxo-2H-chromen-7-yloxymethyl)-[1,2,3]triazol-1-yl]benzenesulfonamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 4-[4-(2-oxo-2H-chromen-7-yloxymethyl)-[1,2,3]triazol-1-yl]benzenesulfonamide
• 英文别名: 4-(4-(((2-oxo-2H-chromen-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)benzenesulfonamide；4-[4-[(2-Oxochromen-7-yl)oxymethyl]triazol-1-yl]benzenesulfonamide；4-[4-[(2-oxochromen-7-yl)oxymethyl]triazol-1-yl]benzenesulfonamide
• 化学式: C₁₈H₁₄N₄O₅S
• 分子量: 398.399
• InChiKey: WIUDCHLBGORNGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  135
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  7-羟基香豆素 在 copper(ll) sulfate pentahydrate 、 potassium carbonate 、 sodium ascorbate 作用下， 以 水 、 丙酮 、 叔丁醇 为溶剂， 反应 13.0h， 生成 4-[4-(2-oxo-2H-chromen-7-yloxymethyl)-[1,2,3]triazol-1-yl]benzenesulfonamide
  参考文献：
  名称：

  Batra, Neha; Rajendran, Vinoth; Wadi, Ishan, Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 2020, vol. 59, # 10, p. 1545 - 1555

  摘要：

  DOI：

文献信息

• Click-tailed coumarins with potent and selective inhibitory action against the tumor-associated carbonic anhydrases IX and XII
  作者：Alessio Nocentini、Fabrizio Carta、Mariangela Ceruso、Gianluca Bartolucci、Claudiu T. Supuran

  DOI：10.1016/j.bmc.2015.09.041

  日期：2015.11

  Coumarins behave as inhibitors of the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) with a mechanism of inhibition distinct from other classes of inhibitors. A series of 7-substituted coumarins incorporating aryl-triazole moieties were prepared by click chemistry procedures starting from 7-hydroxycoumarin or 4-methyl-7-aminocoumarin. The panel of new compounds was assayed for the inhibition of the cytosolic, widespread human (h) isoforms hCA I and II, and the transmembrane, tumor-associated ones hCA IX and XII. Most of the coumarins were weak inhibitors or did not inhibit significantly hCA I and II, but showed low nanomolar inhibitory action against the transmembrane isoforms (K-I of 14.3-34.4 nM against hCA IX and of 4.7-37.8 nM against hCA XII). Since many hypoxic tumors over-express hCA IX/XII, and as these targets were recently validated for obtaining antitumor/antimetastatic agents, with one inhibitor in Phase I clinical trials, the present findings constitute an interesting extension to the knowledge of non-sulfonamide, selective inhibitors of CA isoforms involved in serious pathologies. (C) 2015 Elsevier Ltd. All rights reserved.
• Batra, Neha; Rajendran, Vinoth; Wadi, Ishan, Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 2020, vol. 59, # 10, p. 1545 - 1555
  作者：Batra, Neha、Rajendran, Vinoth、Wadi, Ishan、Ghosh, Prahlad C.、Nath, Mahendra

  DOI：——

  日期：——